Patents Assigned to SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD .
-
Publication number: 20240118263Abstract: Disclosed are target for screening anti-tumor drug, application use thereof and screening method therefor. Disclosed are a target for screening a drug for treating and/or preventing tumors, the target for screening the drug for treating and/or preventing tumors comprise selenoprotein; and a target for screening a drug for preventing tumor metastasis, the target for screening the drug for preventing the tumor metastasis comprising selenoprotein. Also disclosed is a method for screening a drug for treating and/or preventing tumors or a drug for preventing tumor metastasis, the method comprising: interacting a candidate drug with the selenoprotein; and screening the drug for treating and/or preventing tumors or the drug for preventing tumor metastasis according to an affinity between the candidate drug and the selenoprotein; and the candidate drug with a high affinity with the selenoprotein is taken as a candidate primarily screened drug.Type: ApplicationFiled: October 10, 2020Publication date: April 11, 2024Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Enhong JIANG, Weiqing HE, Mingyu XIA, Dong WANG, Xundong JIANG, Xiaofeng ZHAO
-
Publication number: 20230159971Abstract: The present disclosure provides a spiramycin-producing strain, a carrimycin-producing strain, construction method therefor, use thereof and method for increasing the product yield thereof. The provided spiramycin-producing strain has an inactivated gene Lrp (?lrp-SP); and the strain has a preservation number of CGMCC No.16056. The provided carrimycin-producing strain has an inactivated gene Lrp (?lrp-BT); and the strain has a preservation number of CGMCC No.16055. By inactivating the gene Lrp, the yields of spiramycin and carrimycin are increased; and particularly the yield and proportion of a major component of the carrimycin, that is, 4?-O-isovalerylspiramycin III are significantly increased.Type: ApplicationFiled: December 12, 2019Publication date: May 25, 2023Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Enhong JIANG, Weiqing HE, Xiaofeng ZHAO, Xunlei JIANG
-
Patent number: 11413302Abstract: A medicament for preventing and/or treating a disease is disclosed, the disease is Alzheimer's disease, diabetes or senility; and the medicament includes a first active ingredient, and the first active ingredient includes one of carrimycin, isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III, or a combination of two or three of isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III.Type: GrantFiled: January 18, 2019Date of Patent: August 16, 2022Assignee: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Mingyu Xia, Xiaofeng Zhao, Xunlei Jiang, Xundong Jiang
-
Publication number: 20220211735Abstract: A medicament for preventing, alleviating and/or treating fibrosis comprises one of Carrimycin, Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III; or a combination of two or three of Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III. A combination product for preventing, alleviating and/or treating fibrosis comprises a first drug, an effective component of the first drug comprises one of Carrimycin, Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III; or a combination of two or three of Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III. It also relates to use of the medicine and combination product in preventing, alleviating and/or treating fibrosis.Type: ApplicationFiled: April 16, 2020Publication date: July 7, 2022Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Hongwei HE, Enhong JIANG, Weiqing HE, Xundong JIANG
-
Patent number: 11077126Abstract: The present disclosure provides use of carrimycin and pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment of tumors. The carrimycin and the pharmaceutically acceptable salts thereof have good curative effects on breast cancer, liver cancer, lung cancer, renal cancer, brain tumor, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric adenocarcinoma, colon cancer, lymphoma or leukemia and other tumors, and especially have obvious inhibitory effects on the growth of human breast cancer cells MCF-7 and MDA-MB-231, human hepatoma cells HepG2, human non-small cell lung cancer cells A549, human large cell lung cancer cells H460 and H1299, human renal clear cell adenocarcinoma cell 786-O, human renal cell adenocarcinoma cell 769-P, and human glioma cell U251.Type: GrantFiled: April 5, 2018Date of Patent: August 3, 2021Assignee: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Enhong Jiang, Mingyu Xia, Xunlei Jiang, Xundong Jiang
-
Patent number: 11000708Abstract: Use of carrimycin in Mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in Mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated Mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle Bacillus infected diseases are expected to be developed.Type: GrantFiled: December 5, 2016Date of Patent: May 11, 2021Assignee: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Yiguang Wang, Yang Jiang, Xiaofeng Zhao, Weiqing He
-
Publication number: 20200405739Abstract: Disclosed are an mTOR inhibitor, a pharmaceutical composition and use thereof. The mTOR inhibitor includes one of carrimycin, isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III, or a combination of two or three of isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III. The pharmaceutical composition also includes a drug for treating and/or preventing diseases related to the mTOR pathway as a second active ingredient. The mTOR inhibitor has obvious inhibiting effect on cells of diseases related to mTOR pathway, and is used for preparing drugs for treating and/or preventing diseases related to the mTOR pathway.Type: ApplicationFiled: January 18, 2019Publication date: December 31, 2020Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Mingyu XIA, Xiaofeng ZHAO, Xunlei JIANG, Xundong JIANG
-
Patent number: 10858659Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).Type: GrantFiled: November 24, 2016Date of Patent: December 8, 2020Assignee: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Yiguang Wang, Yang Jiang, Xiaofeng Zhao, Weiqing He, Jianlu Dai
-
Publication number: 20200338107Abstract: A medicament for preventing and/or treating a disease is disclosed, the disease is Alzheimer's disease, diabetes or senility; and the medicament includes a first active ingredient, and the first active ingredient includes one of carrimycin, isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III, or a combination of two or three of isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III.Type: ApplicationFiled: January 18, 2019Publication date: October 29, 2020Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Mingyu XIA, Xiaofeng ZHAO, Xunlei JIANG, Xundong JIANG
-
Publication number: 20200163984Abstract: Disclosed are a medicament comprising isovaleryl spiramycin I, II and/or III, and use of isovaleryl spiramycin I, II and/or III in manufacturing medicament for treating and/or preventing tumor and the medicament.Type: ApplicationFiled: July 4, 2018Publication date: May 28, 2020Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Enhong JIANG, Weiqing HE, Jianlu DAI, Yang JIANG, Xunlei JIANG, Xiaofeng ZHAO
-
Publication number: 20200030351Abstract: The present disclosure provides use of carrimycin and pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment of tumors. The carrimycin and the pharmaceutically acceptable salts thereof have good curative effects on breast cancer, liver cancer, lung cancer, renal cancer, brain tumor, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric adenocarcinoma, colon cancer, lymphoma or leukemia and other tumors, and especially have obvious inhibitory effects on the growth of human breast cancer cells MCF-7 and MDA-MB-231, human hepatoma cells HepG2, human non-small cell lung cancer cells A549, human large cell lung cancer cells H460 and H1299, human renal clear cell adenocarcinoma cell 786-O, human renal cell adenocarcinoma cell 769-P, and human glioma cell U251.Type: ApplicationFiled: April 5, 2018Publication date: January 30, 2020Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Enhong JIANG, Mingyu XIA, Xunlei JIANG, Xundong JIANG
-
Publication number: 20190093112Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).Type: ApplicationFiled: November 24, 2016Publication date: March 28, 2019Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Yiguang WANG, Yang JIANG, Xiaofeng ZHAO, Weiqing HE, Jianlu DAI
-
Publication number: 20190001160Abstract: Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.Type: ApplicationFiled: December 5, 2016Publication date: January 3, 2019Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD .Inventors: Yiguang WANG, Yang JIANG, Xiaofeng ZHAO, Weiqing HE